Gamma-retroviral vector production and packaging cell line work —
manufactured in the same organization that runs your cell process.
Gamma-retroviral vector manufacturing produces an integrating vector from a stable packaging or producer cell line. Retroviral vector transduces dividing cells and carries the longest clinical track record in ex-vivo gene therapy — much of the foundational CAR-T and HSC gene therapy dataset was generated on it. Production centres on maintaining and characterizing the producer line, then harvest, purification, fill, and release testing including replication-competent retrovirus testing.
GeneFab is a retroviral vector CDMO manufacturing GMP gamma-retroviral vector, including packaging and producer cell line banking and characterization. Because vector and cell process sit in one organization, programs built on retroviral integration can keep the platform their clinical data was generated on instead of rebuilding comparability from the ground up.
A retroviral program usually arrives with history: a packaging line, a process, and clinical data. These are the pieces we own.
Packaging and producer cell line handling, banking, and characterization — including the testing package a retroviral producer line requires.
Where the program calls for it, payload and regulatory element design from our synthetic biology group, with promoter selection appropriate to retroviral integration.
Retroviral vector production and harvest developed for stability, given the shorter half-life that retroviral vector work has to design around.
Clarification, concentration, and purification developed for the impurity profile your cell process and clinical protocol can tolerate.
Fill into the final container with stability treated as a program deliverable, so supply is scheduled against clinical demand.
Titre, identity, purity, and safety testing developed against the process, with core biosafety tests performed in house.
If your clinical dataset was generated with gamma-retroviral vector, switching platforms means rebuilding comparability from the ground up. Sometimes that is right. Often it is not, and you need a partner who will say so.
Maintaining the retroviral platform preserves the comparability argument your clinical data already supports.
Packaging and producer cell line banking, characterization, and testing treated as a real deliverable, not legacy maintenance.
If lentivirus or non-viral genuinely serves the program better, we will tell you — and we can manufacture that too.
What sponsors ask before choosing a retroviral vector CDMO.
Yes. We manufacture gamma-retroviral vector under GMP, including packaging and producer cell line work, production, purification, fill, and release testing.
Yes. Producer line handling, banking, and characterization — including identity, sterility, adventitious agent, and stability testing — are part of the scope.
Sometimes, but not by default. If your clinical dataset was generated on gamma-retroviral vector, switching means rebuilding comparability. We will give you an honest assessment, and we can manufacture either.
Yes. RCR testing is part of the release package, and core biosafety tests — sterility, mycoplasma, endotoxin, and identity — run in house to keep release timelines short.
Yes. Vector and cell process sit in one organization under one quality system, so they are developed against each other rather than transferred between vendors.
A technical exchange under CDA, then a gap assessment of your line, process, and analytics, a transfer plan, and engineering runs before GMP. Requesting a quote starts that conversation.
